from Business Week;Here is my response.
Shares of Sequenom Inc. surged Friday after the company said demand for its maternal Down syndrome test is improving and it expects to surpass its previous guidance for testing volume.
Sequenom said at the end of October it was handling about 1,700 MaterniT21 Plus samples a week, which projects to a rate of about 90,000 tests per year. The company said it ran about 18,000 of the tests during the third quarter and will "significantly exceed" its estimate of 50,000 billed tests in 2012.Read the entire article here.
Not that pre-natal testing is wrong in itself, but with the extraordinarily high (75-92%) abortion rate when these tests yield a positive result for Down syndrome, does't Sequenom plan on investing any of these profits into education about the research advances made this year testing the first medicines to treat the cognitive delays present with Down syndrome?